Bionik Laboratories Corp. (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing transformational technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced that shares of the Company's common stock will begin trading today on the OTCQX® Best Market under its existing ticker symbol "BNKL."
"Bionik is developing exciting robotic technologies to help people with impaired mobility walk again," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "We are pleased to welcome Bionik to the OTCQX market and look forward to supporting the company in its continued growth and evolution as a publicly-traded company."
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for Bionik on www.otcmarkets.com.
Peter Bloch, CEO of Bionik, stated, "Upgrading to the OTCQX market is an important step forward for Bionik as we continue to focus our efforts on advancing and deploying our innovative medical-robotic healthcare solutions towards commercialization and prepare to execute on our growth strategy."
As previously announced, Bionik successfully raised $13.1 million in a private placement equity financing to implement the Company's vision of becoming a leading medical device and robotics company with a near term core focus on robotic exoskeleton technology for users with mobility impairments.
New study aims to reduce bias in AI health prediction models